A new compound has been shown by researchers at the Walter and Eliza Hall Institute (Melbourne, Australia) and Servier (Neuilly-sur-Seine, France) to block a protein essential to the sustained growth of up to a quarter of all cancers.
Cancer Research Technology (an arm of Cancer Research UK; London, UK) has received a success payment from GlaxoSmithKline (Brentford, UK) as reward for its collaborative research efforts developing molecules targeting cancer epigenetics.
A team from the University of Texas Southwestern (Dallas, TX, USA) have found a potential means by which to treat an ‘undruggable’ form of lung cancer, and have located an existing drug that could provide a treatment.
Research from Rockefeller University (New York, NY, USA) has identified a compound in yeast that interferes with the process by which ribosomes are assembled, potentially opening the door to the development of novel antifungal drugs.
Researchers from Concordia University (Montréal, QC, Canada) and Idunn Technologies (Rosemère, QC, Canada) have assessed how six plant extracts can delay aging, by affecting different pathways that set the pace of growing old.
Researchers from the University of Pennsylvania (Philadelphia, PA, USA) and Fox Chase Chemical Diversity Center (Doylestown, PA, USA) have found a novel kind of chemical compound that could potentially be used to treat Ebola virus infection.
Researchers from the Medical Research Council (Cambridge, UK) and University College London (UK) have discovered a key component of the HIV virus that presents a new drug target, and offers the opportunity to re-evaluate existing HIV therapeutics to improve efficacy.
A collaborative team of researchers have announced that they are one step closer to providing effective therapeutics for three neglected tropical diseases after manufacturing a chemical capable of killing the parasites that causes them.
Researchers from Griffith University (Brisbane, Australia) have collaborated with an international team to advance drug discovery for tropical diseases by creating and testing a panel of chemical compounds termed the ‘Malaria Box’.
Researchers from UT Southwestern Medical Center (Dallas, TX, USA) have identified a novel means of targeting one of the most commonly mutated genes in human cancer, a discovery with potential to treat lung cancer.
A team led by the University of Navarra (Spain) and Jagiellonian University (Krakow, Poland) have discovered a new class of compounds, named selenocompounds, which have the potential to treat multidrug resistant cancer cells.